Childhood uveitis not associated with juvenile idiopathic arthritis: a national survey of incidence, management and visual outcomes.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
27
01
2020
accepted:
28
10
2020
revised:
22
10
2020
pubmed:
18
11
2020
medline:
21
9
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
To estimate the incidence of childhood uveitis not associated with juvenile idiopathic arthritis (JIA) in the United Kingdom. Children under 16 years who presented with a new diagnosis of uveitis from November 2014 to October 2015 were identified prospectively through the British and Scottish Ophthalmological Surveillance Unit reporting card system. Incident questionnaires were sent to reporting ophthalmologists at presentation and 12 months. From 1st November 2014 to 31st October 2015, 119 cases were reported. Thirty-nine cases were excluded. The estimated minimum annual incidence of non-JIA uveitis in children younger than 16 years is 0.66 per 100,000 (95% CI 0.52-0.82). Median age at presentation was 10 years. 73% had bilateral uveitis. Median (IQR) BCVA in the worse eye was 0.3 (IQR 0.1-0.66) logMAR. The location of uveitis was: anterior 36%, intermediate 24%, posterior 6.8% and panuveitis 30%. 70% of cases were idiopathic. Most children were started on topical corticosteroids at presentation (86%, n = 51). At presentation, 31% (n = 19) were on started on systemic corticosteroids. At 1 year only 13% (n = 7) remained on corticosteroids, with the majority transitioned to steroid-sparing agents: methotrexate (30.8%, n = 16), mycophenolate (5.8%) and anti-TNF agents 5 (9.6%). At 1 year, 46% had ongoing intraocular inflammation despite treatment. The most common ocular adverse event was raised intraocular pressure (13.5%, n = 7). Our study provides the first national population-based data of non-JIA childhood uveitis. Most children remain on treatment at 1 year, but visual acuity improves and none were eligible for sight-impairment registration.
Identifiants
pubmed: 33199865
doi: 10.1038/s41433-020-01267-2
pii: 10.1038/s41433-020-01267-2
pmc: PMC8376936
doi:
Substances chimiques
Tumor Necrosis Factor Inhibitors
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2573-2578Informations de copyright
© 2020. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol. 2003;135:676–80.
doi: 10.1016/S0002-9394(02)02148-7
Heiligenhaus A, Heinz C, Edelsten C, Kotaniemi K, Minden K. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm. 2013;21:180–91.
doi: 10.3109/09273948.2013.791701
Moorthy LN, Petersen MG, Hassett AL, Lehman TJA. Burden of childhood-onset arthritis. Pediatr Rheumatol Online J. 2010;8:20.
doi: 10.1186/1546-0096-8-20
Heiligenhaus A, Michels C, Schumacher C, Kopp I, Neudorf U, Niehues T, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32:1121–33.
doi: 10.1007/s00296-011-2126-1
Minden K, Niewerth M, Listing J, Mobius D, Thon A, Ganser G, et al. The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database. Clin Exp Rheumatol. 2009;27:863–9.
pubmed: 19917175
Zannin ME, Birolo C, Gerloni VM, Miseocchi E, Pontikaki I, Paroli MP, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40:74–9.
doi: 10.3899/jrheum.120583
Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–16.
doi: 10.1016/j.ajo.2005.03.057
BenEzra D, Cohen E, Maftzir G. Uveitis in children and adolescents. Br J Ophthalmol. 2005;89:444–8.
doi: 10.1136/bjo.2004.050609
Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology. 2004;111:2299–306.
doi: 10.1016/j.ophtha.2004.06.014
Smith JA, Mackensen F, Sen HN, Leigh JF, Watkins AS, Pyatetsky D, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009;116:1544–51.
doi: 10.1016/j.ophtha.2009.05.002
Cann M, Ramanan AV, Crawford A, Dick AD, Clarke SLN, Rashed F, et al. Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy. Pediatr Rheumatol Online J. 2018;16:51.
doi: 10.1186/s12969-018-0266-5
Gregory AC, Kempen JH, Daniel E, Kacmaz RO, Foster CS, Jabs DA, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120:186–92.
doi: 10.1016/j.ophtha.2012.07.052
Tappeiner C, Klotsche J, Schenck S, Niewerth M, Minden K, Heiligenhaus AL. Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis: data from a cross-sectional analysis of a prospective nationwide study. Clin Exp Rheumatol. 2015;33:936–44.
pubmed: 26517055
Simonini G, Paudyal P, Jones G, Cimaz R, Macfarlane GJ. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology. 2013;2013:825–31.
doi: 10.1093/rheumatology/kes186
Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, et al. (SYCAMORE Study Group). Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376:1637–46.
doi: 10.1056/NEJMoa1614160
Interim Clincical Comissioning Policy: Adalimumab for Children with Severe Refractory Uveitis. D12X02. https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/11/d12x02-paediatric-uveitis-anti-tnf.pdf .
Jaffe GJ, Dick AD, Brezin AP, Ngyuen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932–43.
doi: 10.1056/NEJMoa1509852
Foot B, Stanford M, Rahi J, Thompson J. The British Ophthalmological Surveillance Unit: an evaluation of the first 3 years. Eye. 2002;16:1–7.
doi: 10.1038/sj.eye.6700024